Small molecule (Molecular glue degrader) · Degrader of RNA-binding motif protein 39 (RBM39) · developed by Recursion Pharmaceuticals
REC-1245 is an orally bioavailable molecular glue degrader that targets the splicing factor RBM39. It recruits RBM39 to the E3 ligase adaptor DCAF15, promoting its ubiquitination and proteasome-mediated degradation, which alters RNA splicing and downregulates DNA damage response networks. It is being studied in unresectable, locally advanced or metastatic cancers and relapsed or refractory lymphomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06678659 | Phase 1/2 | Unresectable | Recruiting | RXRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Locally AdvancedMetastatic CancersRelapsed/Refractory LymphomasUnresectable
See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RXRX catalysts and pipeline →